Zobrazeno 1 - 7
of 7
pro vyhledávání: '"329"'
Autor:
Tony Reiman, Donna E. Reece, Eshetu G. Atenafu, Martha L Louzada, Christopher P. Venner, Muhammad Aslam, Michael Sebag, Kevin W. Song, Arleigh McCurdy, Richard Leblanc, Esther Masih-Khan, Julie Stakiw, Darrell White, Engin Gul, Rami Kotb, Victor H Jimenez-Zepeda
Publikováno v:
Blood. 134:1886-1886
Lenalidomide in combination with dex (Len + dex) was introduced as treatment for relapsed/refractory myeloma in Canada over a decade ago; more recently, Len has been routinely available as part of first-line therapy, both in transplant-eligible patie
Publikováno v:
Blood. 132:4979-4979
Background Although significant advances have been made over the past 10 years in the treatment of Immune Thrombocytopenia (ITP), challenges remain in addressing the burden of disease and unmet needs of patients. In rare diseases especially, natural
Autor:
Suzanne R. Hayman, Morie A. Gertz, Steven R. Zeldenrust, Francis K. Buadi, Miriam Hobbs, Moritz Binder, Shaji Kumar, Martha Q. Lacy, Angela Dispenzieri, Wilson I. Gonsalves, Ronald S. Go, Prashant Kapoor, John A. Lust, Robert A. Kyle, Taxiarchis Kourelis, S. Vincent Rajkumar, Rahma Warsame, Amie Fonder, Stephen J. Russell, Nelson Leung, Arjun Lakshman, Lisa Hwa
Publikováno v:
Blood. 132:4497-4497
Background: The introduction of novel therapeutics has led to improved outcomes in patients with multiple myeloma (MM). MM and its precursor lesion smoldering multiple myeloma (SMM) have traditionally been associated with increased mortality despite
Autor:
Andrea Arruda, Steven M. Chan, Mark D. Minden, Hassan Sibai, Georgina S. Daher-Reyes, Aaron D. Schimmer, Jaime O. Claudio, Tracy Stockley, Vikas Gupta, Caroline J McNamara, Suzanne Kamel-Reid, Karen W.L. Yee, Andre C. Schuh, Dawn Maze, Reem Abdulrahman Alkharras, Manjula Maganti, Jose Mario Capo-Chichi
Publikováno v:
Blood. 132:2666-2666
Acute myeloid leukemia (AML) is a clinically and biologically heterogeneous disease. Traditionally, cytogenetic analysis has been the backbone for prognostication and treatment decisions. Outcomes vary between age groups with older adults generally h
Autor:
Nicholas Finn, Nancy Zhu, Martha Lenis, Lisa Chodirker, Brian Leber, Mary-Margaret Keating, Michelle Geddes, Danielle N. Blunt, Kenneth Rockwood, Jill Fulcher, Robert Delage, Versha Banerji, Karen W.L. Yee, Rena Buckstein, Eve St-Hilaire, Mitchell Sabloff, Liying Zhang, Richard A. Wells, Alexandre Mamedov, Mohamed Elemary, April Shamy, Heather A. Leitch
Publikováno v:
Blood. 132:4850-4850
Background: Health-Related Quality of life (HRQoL) is diminished in patients with myelodysplastic syndrome (MDS). We have previously shown that HRQoL remains stable over time and low hemoglobin, transfusion dependence (TD) and age > 65 years impact Q
Autor:
Adam Cuker, Maria Eva Mingot-Castellano, Natasha Satkunam, Julie Grabell, Patrick F. Fogarty, Maria Elisa Mancuso, Pål Andre Holme, Christoph Bidlingmaier, Meera Chitlur, Prasad Mathew, Paula D. James, Wilma M. Hopman, Johnny Mahlangu
Publikováno v:
Blood. 128:875-875
Background: Hemophilia carriers report abnormal bleeding, even when factor VIII or IX levels are normal. Information comparing bleeding events between carriers and women with other inherited bleeding disorders is lacking. Purpose: The purpose of our
Autor:
Shaji Kumar, Sagar Lonial, Suzanne Trudel, Paul G. Richardson, David S. Siegel, Keith Stewart, Martin H. van Vliet, Kenneth C. Anderson, Andrzej Jakubowiak, Donna E. Reece, Sundar Jagannath, Ravi Vij, Rafael Fonseca, Erik H. van Beers, Todd M. Zimmerman, Joan Levy, Ajai Chari, Daniel Lebovic
Publikováno v:
Blood. 122:1854-1854
Introduction Multiple Myeloma is not a single disease. There is increasing support for risk classification in combination with treatment decision making because of its impact on clinical outcomes. Here we demonstrate additional evidence of the progno